Annotation Detail
Information
- Associated Genes
- KRAS
- Associated Variants
-
KRAS EXON 2 MUTATION
KRAS EXON 2 MUTATION - Associated Disease
- pancreatic cancer
- Source Database
- CIViC Evidence
- Description
- In a retrospective study of 136 pancreatic cancer patients, point mutations in KRAS exon 2 were associated with worse overall survival compared to that of wild-type KRAS (5.8 vs 8.0 months; P = 0.001; multivariate analysis). This difference was largely driven by the subgroup of patients with reduced response to gemcitabine-erlotinib combination therapy (7.5% vs 23.3%) with overall survival of 5.2 vs 9.7 months (N=40 vs 30) compared to those that received other therapies with an overall survival of 7.0 months for both KRAS mutated (N=31) and KRAS wildtype (N=35) patients.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1219
- Gene URL
- https://civic.genome.wustl.edu/links/genes/30
- Variant URL
- https://civic.genome.wustl.edu/links/variants/75
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Pancreatic Cancer
- Evidence Direction
- Supports
- Drug
- Gemcitabine,Erlotinib
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 21862683
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Erlotinib | Resitance or Non-Reponse | true |
| Gemcitabine | Resitance or Non-Reponse | true |